Maryland Heart Center
Research Highlights
Selected References for Ashwani Khanna, Ph.D., Director, Cardiac Allograft Vasculopathy Research Laboratory
- Khanna AK and Pieper G. NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and
tacrolimus-induced nephrotoxicity in a rat renal transplant model. Accepted
Nephrol Dial Transplant. 2007 ; 22:376-85.
- Khanna AK, Mehra MR Targeted in vitro and in vivo gene transfer into T lymphocytes:
potential of direct inhibition of allo-immune activation. BMC Immunol. 2006;
7:26-35.
- Khanna A. Reciprocal role of cyclins and cyclin kinase inhibitor p21WAF1/CIP1
on lymphocyte proliferation, allo-immune activation and inflammation. BMC-IMMUNOLOGY,
6: 22-30, 2005.
- Khanna A, Plummer, M, Nilakantan V, and Pieper G. p21 protein inhibits lymphocyte
activation and transcription factors. J Immunology. 2005; 174: 7610-7.
- Khanna AK Tacrolimus and cyclosporine in vitro and in vivo induce osteopontin
mRNA expression in renal tissues. Nephron Exp Nephrol. 2005; 101(4): e119-e126.
- Khanna AK, Plummer MS, Hilton G, Pieper GM and Ledbetter S. Anti-TGF-τ
-antibody at low, but not high doses, limits CsA-mediated nephrotoxicity without
altering rat cardiac allograft survival: potential of therapeutic applications.
Circulation 2004 110: 3822-3829.
- Khanna A. Concerted effect of transforming growth factor-β, cyclin inhibitor
p21, and c-myc on smooth muscle cell proliferation Am J Physiol Heart Circ
Physiol 286: H1133-H1140, 2004.
- Khanna A. Prolongation of Skin Xenograft Survival with modified cultured
fibroblasts. A discussion. Plastic and Reconstructive Surgery 111: 263-265,
2003.
- Khanna AK Tacrolimus induces the Expression of the Cyclin Inhibitor p21
in lymphoid and non-lymphoid cells Biochem Biophys Res Commun. 303:266-72,
2003.
- Pieper GM, Nilakantan V, Hilton G, Halligan NLN, Felix CC, Kampalath B,
Khanna AK, Roza AM, Johnson CP, Adams MB. Mechanism of the protective action
of diethyldithiocarbamate-iron complex on acute cardiac allograft rejection.
Am J Physiol Heart Circ Physiol. 284:H1542-51, 2003.
- Khanna AK, Hosenpud JS, Plummer MS and Hosenpud JD. Analysis of TGF-β
and pro-fibrogenic molecules in a rat cardiac allograft model treated with
Cyclosporine. Transplantation 73: 1543-1549, 2002.
- Khanna AK, Plummer M, Bromberek K, Bresnahan B and Hariharan S. Expression
of TGF-β and Fibrogenic Genes in Transplant Recipients with Tacrolimus
and Cyclosporine Nephrotoxicity. Kidney Int. 62:2257-63, 2002.
- Khanna A, Plummer M, Bromberek K, Woodliff J and Hariharan S. Immuno Modulation
In Stable Renal Transplant Recipients With Concomitant Tacrolimus And Sirolimus
Therapy. BMC Medical Immunology, 1:3-9, 2002.
- Khanna A. Cell cycle control and immunosuppression in organ transplantation.
Transplantation Proc. 33: 2101-2106, 2001.
- Khanna AK. Mechanism of the combination immunosuppressive effects of Rapamycin
with either cyclosporine or tacrolimus. Transplantation 70: 690-694, 2000.
- Khanna A K and Hosenpud JD In vitro and in vivo transfection of p21 gene
enhances Cyclosporine mediated inhibition of lymphocyte proliferation. J Immunology
165: 1882-1888, 2000.
- Khanna A. et al. Augmentation of the expression of proangiogenic genes in
cardiomyocytes with low dose laser irradiation in vitro. Cardiovascular Radiation
Medicine 1: 265-269, 1999.
- Khanna A, Cairns V, and Hosenpud JD. Tacrolimus induces increased expression
of transforming growth factor-beta in lymphoid and non-lymphoid cells. Transplantation
67: 614-619, 1999.
- Khanna A, Cairns V, Becker CG and Hosenpud JD. Transforming Growth Factor-β
(TGF-β) mimics and anti-TGF-β antibody abrogates the in-vivo effects
of Cyclosporine: demonstration of a direct role of TGF-β in immunosuppression
and nephrotoxicity of CsA. Transplantation 67: 882-889, 1999.
- Khanna AK and Hosenpud, JD. Cyclosporine induces the expression of the cyclin
inhibitor p21. Transplantation 67: 1262-1268, 1999.
For More Information
Please call if you would like to make an
appointment or talk to someone about our services. Patients dial 1-800-492-5538
or 410-328-5842, physicians dial 410-328-6622 or 1-800-318-1019.